Humulin M3 (Mixture 3) (Insulin Human (Rdna))

Humulin M3 is indicated for the treatment of both type 1 and type 2 diabetes mellitus when a mixed insulin regimen is appropriate. It is used to improve glycemic control in patients who require basal and prandial insulin coverage.

• Initiation of insulin therapy in newly diagnosed diabetic patients who need both basal and mealtime insulin.
• Switching from separate basal and rapid‑acting insulins to a single mixed formulation.
• Adjusting insulin dose in patients with variable meal patterns.
• Use in conjunction with diet, exercise, and oral antidiabetic agents when additional glucose lowering is needed.
• Management of fasting and post‑prandial blood glucose levels.

• Humulin M3 provides insulin that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers intracellular signaling cascades that promote glucose uptake into peripheral tissues and suppress hepatic glucose production, thereby lowering blood glucose concentrations. The mixed formulation contains both short‑acting and intermediate‑acting insulin components, delivering rapid onset and prolonged activity to cover meals and basal needs.

Adverse reactions to Humulin M3 can range from mild to severe. Patients should be aware of both common and serious potential effects.

Common

• Hypoglycemia (low blood sugar)
• Injection site redness, swelling, or itching
• Lipodystrophy (fat tissue changes at injection site)
• Weight gain
• Mild nausea

Serious

• Severe hypoglycemia requiring assistance
• Allergic reactions such as rash, urticaria, or anaphylaxis
• Edema (fluid retention)
• Persistent hyperglycemia indicating inadequate dosing
• Rare cases of insulin antibody formation.

Before using Humulin M3, certain precautions should be considered to ensure safe and effective therapy.

• Verify blood glucose levels regularly to avoid hypoglycemia.
• Adjust doses during periods of illness, stress, or changes in physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be altered.
• Monitor for signs of allergic reactions, especially after the first few injections.
• Pregnant or breastfeeding women should discuss risks and benefits with a healthcare professional.
• Store the product according to label instructions and discard after the recommended in‑use period.

Humulin M3 may interact with other medications, affecting glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.
• High‑dose beta‑blockers that may mask hypoglycemia symptoms.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which can raise blood glucose and require insulin dose increase.
• Diuretics, especially thiazides, that may affect electrolyte balance and glucose levels.
• Alcohol, which can cause unpredictable glucose fluctuations.
• Certain antihypertensive drugs (e.g., ACE inhibitors) that may potentiate insulin's glucose‑lowering effect.